Trial · NCT05177536
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05177536, Phase 2, Active not recruiting, University of Nebraska
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Iberdomide Maintenance Therapy in Patients With Multiple Myeloma. Trials, record NCT05177536. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05177536
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
- NCT number
- NCT05177536
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, actual
- Lead sponsor
- University of Nebraska
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide
- First posted
- 2022-01-04
- Last updated
- 2026-06-11
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants Able to Complete a Minimum of One Year of Ttherapy | 1 year | The number of eligible participants who remain on study receiving iberdomide for at least one year without disease progression among all eligible study participants who began protocol treatment will be determined. |
| Secondary | Median Progression-free Survival | 5 years | Progression-free survival (PFS) for all participants will be determined. This defined as the time from enrollment to documentation of disease progression, using 2016 International Myeloma Working Group (IMWG) Response Criteriacriteria, or death without disease progression. |
| Secondary | Minimal Residual Disease-negativity Rate at Day 100 | 100 Days | An estimate of the Minimal Residual Disease (MRD)-negativity rate at day 100 post-initiation of maintenance therapy will be made. |
| Secondary | Minimal Residual Disease-negativity Rate at One Year | 1 year | An estimate of the Minimal Residual Disease (MRD)-negativity rate at one year post-initiation of maintenance therapy will be made. |
| Secondary | Minimal Residual Disease-negativity Rate at Two Years | 2 years | An estimate of the Minimal Residual Disease (MRD)-negativity rate at two years post-initiation of maintenance therapy will be made. |
| Secondary | Sustained Minimal Residual Disease-negativity Rate | 1 year | The sustained Minimal Residual Disease (MRD)-negativity rate, defined as MRD-negativity at study entry and at one year post-initiation of maintenance therapy will be determined. |
| Secondary | Rate of Conversion From Minimal Residual Disease-positive to Minimal Residual Disease-negative | 1 year | The percentage of participants found to be Minimal Residual Disease (MRD) positive at enrollment and MRD negative at one year post-initiation of maintenance therapy among participants meeting the criteria for MRD-positivity at enrollment will be determined. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05177536
GET https://conductscience.org/api/trials/v1/NCT05177536/registered